Table 1 Comparison of Liquid Biopsy Tests for Early Detection of Single Cancers
Company | Test | Target detection | Molecular origin | Specificity (%) | Sensitivity (%) | Turnaround time (cost/proposed cost) |
|---|---|---|---|---|---|---|
Dxcover [108] (UK) | Dxcover brain cancer liquid biopsy-sensitivity tuned model | Brain cancer | Pan-omic Spectroscopic Assay from blood serum | 45 | 96 | 1Â day ($300) |
Dxcover brain cancer liquid biopsy-specificity tuned model | 90 | 47 | ||||
Guardant health [114] (USA) | Shieldâ„¢ | Colorectal cancer | Shield is a qualitative blood test, intended to detect colorectal neoplasia through identifying genomic and epigenomic alterations in cfDNA, and proteomic changes in plasma from blood collected in guardant blood collection tubes | 92.0 | 91.0 | Around 2Â weeks after the lab receives the samples [115] ($895) [116] |
Novigenix [117] (Switzerland) | Colox | Colorectal cancer | Analysis of peripheral blood mononuclear cells isolated from blood sample | 92.2 | 78.1 | 1–2 weeks. ($290) [118] |
Biodesix [99] (USA) | Nodify cdt | Lung cancer | Autoantibodies on an enzyme-linked immunosorbent assay (ELISA) platform from blood | 98 | 28 | 1Â day ($649) [119] |
Biodesix [120] (USA) | Nodify xl2 | Lung cancer | Measures proteins from blood with liquid chromatography - mass spectrometry | 44 | 97 | 4–5 days ($3850) [121] |
Biodesix [100] (USA) | Oncimmune EarlyCDT-lung test stage I/II (Biodesix, USA) | Lung cancer | ELISA platform that measures autoantibodies from blood | 90.3 | 52.2 |  ~ 10 working days. ($84.98a/£70) [122] |
Oncimmune EarlyCDT-lung test stage III/IV (Biodesix, USA) | 90.2 | 18.2 | ||||
Abcodia [123] (UK) | ROCA | Ovarian cancer | The ROCA test uses CA-125 measurements to establish a patient’s baseline levels of CA-125 to give an individualized profile of change over time, from a blood sample | 87.6 | 87.1 | Turnaround time - ($182.11a/£150) [124] |
ExοDx [78] (USA) | ExoDx (EPI) prostate Intelliscore | Prostate cancer | Non-invasive exosome-based liquid biopsy, which quantifies three RNA targets in urine exosomes | 30.1 | 92.3 | 1 week after lab receiving sample. ($795) [125] |
MDxHealth [113] (Belgium) | SelectMdx | Prostate cancer | Measures the expression of two mRNA cancer-related biomarkers combined with clinical risk factors to stratify patients for clinically significant prostate cancer from a urine sample | 53 | 89 | 5 business days. ($364.22a/£300) [126] |
4Kscore test | Prostate cancer | A follow-up blood test after an abnormal PSA or digital rectal exam which measures four prostate-specific kallikreins and clinical results to determine the probability of finding aggressive rostate cancer if a biopsy was performed | 27.4 | 96.9 | 2–3 days from lab receiving sample. ($760) [129] |